Inhibikase Therapeutics, Inc.

NasdaqCM:IKT Stock Report

Market Cap: US$13.8m

Inhibikase Therapeutics Management

Management criteria checks 3/4

Inhibikase Therapeutics' CEO is Milton Werner, appointed in Jun 2010, has a tenure of 13.75 years. total yearly compensation is $744.06K, comprised of 67.3% salary and 32.7% bonuses, including company stock and options. directly owns 14.37% of the company’s shares, worth $1.98M. The average tenure of the management team and the board of directors is 9.4 years and 3.3 years respectively.

Key information

Milton Werner

Chief executive officer

US$744.1k

Total compensation

CEO salary percentage67.3%
CEO tenure13.8yrs
CEO ownership14.4%
Management average tenure9.4yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Jan 25
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Aug 26

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Aug 12

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Aug 09
Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06
Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Inhibikase Therapeutics prices stock offering at $3

Jun 16

CEO Compensation Analysis

How has Milton Werner's remuneration changed compared to Inhibikase Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$744kUS$501k

-US$18m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$611kUS$455k

-US$15m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$961kUS$293k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$385kUS$293k

-US$6m

Sep 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$535kUS$452k

-US$2m

Compensation vs Market: Milton's total compensation ($USD744.06K) is about average for companies of similar size in the US market ($USD661.05K).

Compensation vs Earnings: Milton's compensation has increased whilst the company is unprofitable.


CEO

Milton Werner (59 yo)

13.8yrs

Tenure

US$744,055

Compensation

Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...


Leadership Team

NamePositionTenureCompensationOwnership
Milton Werner
CEO, President & Director13.8yrsUS$744.06k14.37%
$ 2.0m
Joseph Frattaroli
Chief Financial Officer5.9yrsUS$574.77k0.011%
$ 1.5k
Roger Rush
Head of Preclinical Research9.2yrsno datano data
Surendra Singh
Head of Chemistry9.6yrsno datano data
Charles Olanow
CEO of Clintrex Research Corporation & Member of Scientific Advisory Boardno datano datano data
Dan Williams
Controllerno datano datano data

9.4yrs

Average Tenure

Experienced Management: IKT's management team is seasoned and experienced (9.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Milton Werner
CEO, President & Director13.8yrsUS$744.06k14.37%
$ 2.0m
Charles Olanow
CEO of Clintrex Research Corporation & Member of Scientific Advisory Boardno datano datano data
Paul Grint
Independent Director3.3yrsUS$84.62k0%
$ 0
Dennis Berman
Independent Director3.3yrsUS$78.62k0%
$ 0
Kenneth Marek
Member of Scientific Advisory Boardno datano datano data
Jeffrey Kordower
Member of Scientific Advisory Boardno datano datano data
Roy Freeman
Independent Director3.3yrsUS$69.62k0%
$ 0
Robert Hauser
Member of Scientific Advisory Boardno datano datano data
Karl Kieburtz
Member of Scientific Advisory Boardno datano datano data
Gisele Dion
Independent Director1.5yrsUS$58.89kno data
Ted Dawson
Member of Scientific Advisory Boardno datano datano data
Valina Dawson
Member of Scientific Advisory Boardno datano datano data

3.3yrs

Average Tenure

65yo

Average Age

Experienced Board: IKT's board of directors are considered experienced (3.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.